June 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountrheumnow.com
Global Rank
#739,758
276,457Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
40.15%
Pages per Visit
1.99
Avg Visit Duration
00:01:48
- Company
- - -
- Industry
- - -
Top 10 rheumnow.com Competitors
The Top 10 Sites Like rheumnow.com in June 2026 are ranked by their affinity to rheumnow.com in terms of keyword traffic, audience targeting, and market overlap
Objective To evaluate the feasibility, usability and acceptability of implementing a treat-to-target (T2T) strategy supported by a Clinical Decision Support System (CDSS), in routine SLE outpatient care.Methods A 24-week, non-randomised, multicentre, clustered pilot study was conducted across four rheumatology outpatient centres. Adult patients with SLE were allocated by centre to either a T2T strategy supported by a CDSS (T2T-CDSS) or a routine outpatient care (ROC) group. The CDSS provided evidence-based treatment recommendations based on disease activity measures. Feasibility outcomes included recruitment and retention rates. Usability was assessed with the System Usability Scale (SUS), completed by physicians in the T2T-CDSS group. Acceptability was evaluated using the Treatment Satisfaction Questionnaire (TSQ) and qualitative feedback. Exploratory outcomes included disease activity, remission rates and treatment modifications.Results Of 91 screened patients, 38 were enrolled (recruitment rate 42%) and 35 completed the study (retention rate 92%). The SUS score for the CDSS was 73.8, indicating good usability. Global satisfaction scores on the TSQ were stable over time and comparable between groups. Remission was achieved at least once by 61% (11/18) of patients in the T2T-CDSS group and 59% (10/17) in the ROC group. Both treatment intensifications and de-escalations occurred more frequently in the T2T-CDSS group compared with ROC (83% vs 47%). Treatment intensifications were observed in 61% of patients in the T2T-CDSS group vs 29% in the ROC group. Treatment de-escalation, represented by glucocorticoid tapering, occurred in 39% of T2T-CDSS patients compared with 18% in ROC. No statistically significant differences were observed between groups in disease activity outcomes or remission rates.Conclusions Implementation of a T2T strategy supported by a CDSS in SLE outpatient care was feasible, usable and acceptable to patients and physicians. Although qualitative fe
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
67.42%
Pages per Visit
1.53
Avg Visit Duration
00:00:06
Similarity Score
100%Though she's felt agitated recently, columnist Rena Newman is trying to walk in forgiveness and find peace amid her health issues.
- Company
- - -
- Industry
- - -
Global Rank
#3,455,768
1,442,776Bounce Rate
59.3%
Pages per Visit
1.60
Avg Visit Duration
00:02:23
Similarity Score
92%The syndrome of periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA syndrome) is the most common cause of periodic fever in childhood. The current pharmacological treatment includes corticosteroids, which usually are efficacious in the management of fever episodes, colchicine, for the prophylaxis of febrile episodes, and other medication for which efficacy has not been proven so far. Tonsillectomy is an option for selected patients. Usually PFAPA syndrome resolves during adolescence, but there is increasing evidence that this condition may persist into adulthood.
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
52.86%
Pages per Visit
1.89
Avg Visit Duration
00:00:02
Similarity Score
89%Sales & Marketing Director Frazer Mackenzie-Andrew 0414 958 144 frazer@medicalrepublic.com.au Production & Client Services Manager Sarah Stanbridge 0413 027 802 sarah@medicalrepublic.com.au Sales Manager (part-time) Sarah Wylie 0412 511 421 swylie@medicalrepublic.com.au EDITORIAL ENQUIRIES (and submissions) Rheuma Republic accepts submissions from contributors and experts for publication. Contact Dr Irwin Lim or Amanda Sheppeard below. Editor in Chief […]
- Company
- - -
- Industry
- - -
Bounce Rate
33.33%
Pages per Visit
2.52
Avg Visit Duration
00:00:18
Similarity Score
87%Skincareguide.com Ltd. (“SkinCareGuide”) understands how important the privacy of personal information is to our customers. SkinCareGuide is committed to honoring your privacy. The document you are reading is our privacy policy for our websites that are accessible by patients/consumers and medical professionals. It describes what information we may collect about you, what uses we may […]
- Company
- - -
- Industry
- - -
Global Rank
#955,536
196,858Bounce Rate
50.11%
Pages per Visit
1.45
Avg Visit Duration
00:00:17
Similarity Score
85%- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
22.25%
Pages per Visit
7.56
Avg Visit Duration
00:04:12
Similarity Score
81%Congress of Clinical Rheumatology Privacy Policy Your privacy and safety of your data is important to us. This Privacy Policy document describes types of information that is or may be collected, used or shared by www.ccrheumatology.com when you visit, use or make a purchases. If you have any additional questions or require more information about […]
- Company
- - -
- Industry
- - -
Bounce Rate
28.8%
Pages per Visit
6.38
Avg Visit Duration
00:02:00
Similarity Score
76%If you have a pit, nodule or cord in your palm and/or the finger associated with it begins to draw into your palm, you may have Dupuytren’s Contracture (no special test is needed to diagnose this condition)
- Company
- - -
- Industry
- - -
Bounce Rate
41.89%
Pages per Visit
2.02
Avg Visit Duration
00:00:27
Similarity Score
72%According to a new report from the American College of Rheumatology (ACR), rheumatology care can save health systems more than $2,700 per patient per year.
- Company
- - -
- Industry
- - -
Bounce Rate
47.35%
Pages per Visit
1.86
Avg Visit Duration
00:00:49
Similarity Score
68%- Company
- Radiography Journal
- Industry
- Health > Medicine
Global Rank
#1,016,437
399,266Bounce Rate
39.24%
Pages per Visit
2.14
Avg Visit Duration
00:00:21
Similarity Score
67%rheumnow.com's top 5 competitors in June 2026 are: lupus.bmj.com, sjogrenssyndromenews.com, ped-rheum.biomedcentral.com, rheuma.com.au, and more.
According to Similarweb data of monthly visits, rheumnow.com’s top competitor in June 2026 is lupus.bmj.com. rheumnow.com 2nd most similar site is sjogrenssyndromenews.com, and closing off the top 3 is ped-rheum.biomedcentral.com.
rheuma.com.au ranks as the 4th most similar website to rheumnow.com and skintherapyletter.com ranks fifth in June 2026.
The other five competitors in the top 10 list are my.rheumatology.org, ccrheumatology.com, northfloridahandandwrist.com, remissionmedical.com, and radiographyonline.com.